Amid disruption in Ukraine, international partnerships are preserving oncology progress—and building the foundation for long-term recovery.
Studies presented at this year’s San Antonio Breast Cancer Symposium shed light on new investigational therapies for patients with...
Guest Post by Kent Osborne, MD Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine;...
On Monday, the U.S. Food and Drug Administration (FDA) rounded out an exciting month for the multiple myeloma community...
As lung cancer awareness month drew to a close, the U.S. Food and Drug Administration (FDA) added another therapeutic...
Guest post by Roy S. Herbst, MD, PhD Yale Comprehensive Cancer Center
On Monday, the U.S. Food and Drug Administration (FDA) announced that it had approved the use of the immunotherapeutic...
The flurry of decisions from the U.S. Food and Drug Administration (FDA) on investigational anticancer therapeutics continued last week...
Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the lung cancer community during...
Last week, the U.S. Food and Drug Administration (FDA) approved the use of cobimetinib (Cotellic) in combination with vemurafenib...
The AACR’s disparities conference covered a wide array of issues this year, from the biological factors that make some...